Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2020-001527-14-NL
EUCTR2020-001527-14-NL
Active, not recruiting
Phase 1

COVID-19: addition of azithromycin to chloroquine treatment - CO VOR IT

Erasmus MC0 sites60 target enrollmentApril 6, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
COVID-19
Sponsor
Erasmus MC
Enrollment
60
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 6, 2020
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Erasmus MC

Eligibility Criteria

Inclusion Criteria

  • •Proven diagnosis of COVID\-19 by positive PCR in any specimen \< 48 hours prior to randomization.
  • •Age \= 18 year
  • •Hospitalized patients with illness of any duration, and SpO2 \= 94% on room air
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 30
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 30

Exclusion Criteria

  • •Severe hypoxemic respiratory failure expected to die \< 72 hours after admission
  • •ICU admission \< 72 hours
  • •Allergy for chloroquine or azithromycin
  • •QT\-prolongation: pre\-existent: QTc males \>450ms, QTc females \> 470ms at day 1 and at day 2
  • •Myasthenia gravis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Suspended
Phase 3
COVID-19: addition of azithromycin to chloroquine treatmentCOVID-19 infection10024970
NL-OMON49080Erasmus MC, Universitair Medisch Centrum Rotterdam60
Active, not recruiting
Phase 1
Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) - Randomised Controlled Trial, phase III
EUCTR2020-001456-18-CZadacní fond Donatio intensivistam240
Not yet recruiting
Phase 3
Efficay of two hydroxychloroquine based drug combination regimens in comparison to standard of care in The Treatment of Hospitalized COVID-19 PatientsCOVID 19
PACTR202010519682638ational Institute for Pharmaceutical Research and Development NIPRD210
Completed
Not Applicable
Anti Infective Agents Impact in COVID-19 PneumoniaCOVIDPneumonia, Viral
NCT04453501Centre d'Investigation Clinique et Technologique 805132
Completed
Phase 2
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South AmericaMalaria, Falciparum
NCT00084227Pfizer244